Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

Open access
Morita, Kiyomi, Kantarjian, Hagop M., Wang, Feng, Yan, Yuanqing, Bueso-Ramos, Carlos, Sasaki, Koji, Issa, Ghayas C., Wang, Sa, Jorgensen, Jeffrey, Song, Xingzhi, Zhang, Jianhua, Tippen, Samantha, Thornton, Rebecca, Coyle, Marcus, Little, Latasha, Gumbs, Curtis, Pemmaraju, Naveen, Daver, Naval, DiNardo, Courtney D., Konopleva, Marina, Andreeff, Michael, Ravandi, Farhad, Cortes, Jorge E., Kadia, Tapan, Jabbour, Elias, Garcia-Manero, Guillermo, Patel, Keyur P., Futreal, P. Andrew, Takahashi, Koichi · 2018 · Journal of Clinical Oncology

Abstract

Purpose: The aim of the current study was to determine whether the degree of mutation clearance at remission predicts the risk of relapse in patients with acute myeloid leukemia (AML). Patients and Methods: One hundred thirty-one previously untreated patients with AML who received intensive induction chemotherapy and attained morphologic complete remission (CR) at day 30 were studied. Pretreatment and CR bone marrow were analyzed using targeted capture DNA sequencing. We analyzed the association between mutation clearance (MC) on the basis of variant allele frequency (VAF) at CR (MC2.5: if the VAF of residual mutations was < 2.5%; MC1.0: if the VAF was < 1%; and complete MC [CMC]: if no detectable residual mutations) and event-free survival, overall survival (OS), and cumulative incidence of relapse (CIR). Results: MC1.0 and CMC were associated with significantly better OS (2-year OS: 75% v 61% in MC1.0 v non-MC1.0; P = .0465; 2-year OS: 77% v 60% in CMC v non-CMC; P = .0303) and lower CIR (2-year CIR: 26% v 46% in MC1.0 v non-MC 1.0; P = .0349; 2 year-CIR: 24% v 46% in CMC v non-CMC; P = .03), whereas there was no significant difference in any of the above outcomes by MC2.5. Multivariable analysis adjusting for age, cytogenetic risk, allogeneic stem-cell transplantation, and flow cytometry–based minimal residual disease revealed that patients with CMC had significantly better event-free survival (hazard ratio [HR], 0.43; P = .0083), OS (HR, 0.47; P = .04), and CIR (HR, 0.27; P < .001) than did patients without CMC. These prognostic associations were stronger when preleukemic mutations, such as DNMT3A, TET2, and ASXL1, were removed from the analysis. Conclusion: Clearance of somatic mutation at CR, particularly in nonpreleukemic genes, was associated with significantly better survival and less risk of relapse. Somatic mutations in nonpreleukemic genes may function as a molecular minimal residual disease marker in AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.77.6757

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 180

Metadata

Authors
Morita, K., Kantarjian, H. M., Wang, F., Yan, Y., Bueso-Ramos, C., Sasaki, K., Issa, G. C., Wang, S., Jorgensen, J., Song, X., Zhang, J., Tippen, S., Thornton, R., Coyle, M., Little, L., Gumbs, C., Pemmaraju, N., Daver, N., DiNardo, C. D., Konopleva, M., Andreeff, M., Ravandi, F., Cortes, J. E., Kadia, T., Jabbour, E., Garcia-Manero, G., Patel, K. P., Futreal, P. A., & Takahashi, K.
Venue
Journal of Clinical Oncology
Published
2018-06-20
Volume
36
Issue
18
Pages
1788-1797
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2799371335
Cited by
180
References
8
FWCI
16.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1200/jco.2017.77.6757
The paper
Morita, K., Kantarjian, H. M., Wang, F., Yan, Y., Bueso-Ramos, C., Sasaki, K., Issa, G. C., Wang, S., Jorgensen, J., Song, X., Zhang, J., Tippen, S., Thornton, R., Coyle, M., Little, L., Gumbs, C., Pemmaraju, N., Daver, N., DiNardo, C. D., . . . Takahashi, K. (2018). Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.77.6757

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.